Grifols, S.A. – American Depositary Downgraded to “Neutral” at Zacks (GRFS) .

01/08/2013 . B.Sabadell cambia el Rating de Grifols a Vender cn un Precio objetivo de 26.13 euros .

******************

August 5th, 2013 . Grifols, S.A. – American Depositary (NASDAQ:GRFS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued on Friday, ARN reports. They currently have a $33.40 price target on the stock. Zacks‘ price objective would suggest a potential upside of 2.61% from the company’s current price.

Separately, analysts at Berenberg Bank raised their price target on shares of Grifols, S.A. – American Depositary to $30.60 in a research note to investors on Tuesday, May 7th. They now have a “hold” rating on the stock.

Grifols, S.A. – American Depositary (NASDAQ:GRFS) traded down 1.27% on Friday, hitting $32.55. Grifols, S.A. – American Depositary has a 1-year low of $19.0476 and a 1-year high of $33.12. The stock’s 50-day moving average is currently $29.44. The company has a market cap of $22.134 billion and a price-to-earnings ratio of 56.75.

Una proteína que acelera el envejecimiento frena el cáncer .

* El hallazgo de la prelamina A podría inspirar nuevas terapias .

* La activación del supresor tumoral más estudiado es la proteína p53 .

* El riesgo de aparición de tumores aumenta con la edad .

Un trabajo científico, fruto de varios años de colaboración entre el Instituto de Medicina Oncológica y Molecular de Asturias (Imoma) y la Universidad de Oviedo, y que ha contado con la participación de científicos ingleses y alemanes, ha revelado que la prelamina A, una proteína que causa envejecimiento acelerado, es capaz de frenar la progresión de los tumores malignos.

Este hallazgo supone un avance para la comprensión de la relación entre los mecanismos que causan el envejecimiento y los que desencadenan el cáncer. Los resultados obtenidos se publican este martes en la revista 'Nature Communications'.

...

Cáncer de Mama . Algunos Antihipertensivos, Vinculados con un Mayor Riesgo en Posmenopáusicas .

Las mujeres mayores que toman ciertos tipos de medicamentos para combatir la presión arterial alta pueden tener mayor riesgo de desarrollar cáncer de mama, según un nuevo estudio realizado por un equipo de científicos del Centro de Investigación del Cáncer Fred Hutchinson, en Seattle (Estados Unidos), dirigidos por Christopher Li.

El estudio, publicado en la revista 'JAMA Internal Medicine', es el primero en observar que el uso a largo plazo de una clase de fármacos antihipertensivos conocidos como bloqueadores de los canales de calcio, en particular, están asociados con el riesgo de cáncer de mama.

...

Alzheimer y Parkinson no parecen compartir el mismo riesgo genético .

Combination Chemotherapy with Torisel ( Pfizer ) and Yondelis ( Pharma Mar ) in Patients with Heavily Pretreated clear cell Carcinoma of the Ovary. .

Masashi Takano, Hiroko Kouta, Naoki Sasaki, Kazuya Kudoh, Tsunekazu Kita, Ryoko Kikuchi, Katsutoshi Oda, Tomoko Goto, Kenichi Furuya, Yoshihiro Kikuchi; Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Japan; National Defense Medical College, Tokorozawa, Japan; National Hospital Organization, Nishisaitama Chuo Hospital, Tokorozawa, Japan; Nara Prefectural Nara Hospital, Nara, Japan; Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan .

Background: Clear cell carcinoma (CCC) of the ovary showed exceedingly chemo-resistant phenotype, especially in the case with recurrent or refractory to previous therapy. An inhibitor against the mammalian target of rapamycin (mTOR), temsirolimus, has been reported to be effective in renal CCC. Additionally, a marine natural product, trabectedin, had activity against recurrent ovarian cancers. We evaluated the effect of combination therapy with temsirolimus and trabectedin for patients with recurrent/refractory CCC of the ovary.

Methods: Patients with recurrent/refractory CCC of the ovary were treated with weekly regimen using two drugs: 10mg/m2 of temsirolimus and 0.15mg/m2 of trabectedin (3 weeks, one week rest) with written informed consents.

Treatment was continued until development of progressive disease (PD) or unmanageable adverse effects. Responses were evaluated by RECIST criteria, and adverse effects were analyzed by NCI-CTCAE v4.0.

Results: A total of 12 patients treated with the regimen, and there were no cases that discontinued the therapy due to toxicities. Median age was 60 years (range: 42-69), and median number of previous chemotherapy was 3 (range: 1-5). All cases were assessable by RECIST and CTCAE. One patient (8%) had a complete response (CR), and another (8%) achieved a partial response (PR), and 4 patients (33%) had stable disease (SD) beyond three months, resulting in clinical benefit rate (CBR; CR+PR+SD>3month) of 50%. Median response duration in CBR case was 3.5 months (range: 3-12+). There were no cases that developed toxicities more than grade2.

Conclusions: The present preliminary study demonstrated combination therapy with temsirolimus and trabectedin was effective in patients with recurrent/refractory CCC of the ovary. These results warrant further study in such clinical settings.